Can cannabis curb opioid cravings? new study aims to find out
NCT ID NCT07668635
First seen Jun 27, 2026 · Last updated Aug 21, 2026 · Updated 2 times
Summary
This study will test whether cannabis can reduce the desire to take opioids in people with opioid use disorder. Thirty participants will live in a hospital for six weeks and receive either cannabis or a placebo, along with opioids. Researchers will measure how many times participants choose to take opioids when given the option.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- cannabis
- What this could lead to
- If it works, this could point toward a way to use cannabis to help people with opioid use disorder reduce their opioid use.
- What could go wrong
- This is a very early Phase 1 study with only 30 people. It is designed to measure behavior, not to treat the disorder, so results may not lead to a new treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
About 30 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Sep 2026
An estimate. Start dates often move.
- Expected to finish
-
Jul 2031
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 55 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Participants with moderate to severe opioid use disorder who experience opioid withdrawal * No allergies or adverse reactions to cannabis or opioids * Willing to stay inpatient at the UK Hospital research center for approx. 6 weeks Exclusion Criteria: * Individuals seeking treatment for opioid use disorder
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cannabis use are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
University of Kentucky Center on Drug and Alcohol Research
Lexington, Kentucky, 40508, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can exercise boost brain and body health during opioid treatment?
- Can a new drug calm the storm of opioid withdrawal?
- Can coaching turn rural clinics into One-Stop shops for addiction and infectious disease care?
- Can rewards and remote coaching help people cut back on cannabis?
- Can a Phone-Based platform keep people in opioid treatment?
- A safety net after jail: can checkups keep opioid treatment on track?